Peptide record

TPDB10614

Antibacterial Hemolysis Toxicity standard
25 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10614
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia PD_Hemolysis
standard
No
A 25-aa standard-residue multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
GKYGFYTHVFRLKKWIQKVIDQFGE
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C149H219N37O35
ANCMPS
K
3088.61
10.13
6
2
11
+3
1.37
-0.524
70.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
8480
2.75
5
Residue Composition
number
0
A
1
R
0
N
1
D
0
C
1
E
2
Q
3
G
1
H
2
I
1
L
4
K
0
M
3
F
0
P
0
S
1
T
1
W
2
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 1 C: 0 E: 1 Q: 2 G: 3 H: 1 I: 2 L: 1 K: 4 M: 0 F: 3 P: 0 S: 0 T: 1 W: 1 Y: 2 V: 2
Chemical Descriptors
25 reviewed residue count
C149H219N37O35 sequence-only estimate (linear, free termini)
3088.61 sequence-only estimate (linear, free termini)
10.13 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
1.37 sequence-only estimate (linear, free termini)
-0.524 sequence-only estimate (linear, free termini)
Evidence Records 7 records
Evidence 1 Activity

Activity

MIC
Antibacterial
2.5 µM

Target

Escherichia coli

Source & Reference

NA

Other

zone inhibition: active against E. coli (MIC 2.5 uM), P. aeruginosa, S. aureus (MIC 5-20 uM), and C. albicans ( Kasetty et al., 2011 ).
Evidence 2 Activity

Activity

MIC
Antibacterial
5-20 µM

Target

Staphylococcus aureus

Source & Reference

NA

Other

zone inhibition: active against E. coli (MIC 2.5 uM), P. aeruginosa, S. aureus (MIC 5-20 uM), and C. albicans ( Kasetty et al., 2011 ).
Evidence 3 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Proteolysis of human thrombin generates novel host defense peptides. | PLoS Pathog | 2010
Evidence 4 Activity

Activity

3% Hemolysis
Toxicity
120 µM
Hemolytic Cytotoxic
3% Hemolysis | 120 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Proteolysis of human thrombin generates novel host defense peptides. | PLoS Pathog | 2010
Evidence 5 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Proteolysis of human thrombin generates novel host defense peptides. | PLoS Pathog | 2010
Evidence 6 Activity

Activity

69.5% Hemolysis
Toxicity
200 µg/mL
Hemolytic Cytotoxic
69.5% Hemolysis | 200 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Thrombin-Derived Peptides Potentiate the Activity of Gram-Positive-Specific Antibiotics against Gram-Negative Bacteria. | Molecules | 2021
Evidence 7 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis